HAE
HAEMONETICS CORPCompany Intelligence Hub
Filing history, signal momentum, and bull/bear evolution
Chronological Filing Evolution (Click to filter / toggle)
Thesis (Bull Case Evolution)
Haemonetics is aggressively transforming from a cyclical blood-collection company into a high-margin medical technology compounder.…
Antithesis (Bear Case / Structural Risks)
Despite the narrative of transformation, Haemonetics faces a troubling trend of shrinking core revenues, with net revenues dipping to $1.33 billion.…
Read the full bull/bear analysis
You are reading the free preview. Start a free trial to unlock the complete bull & bear analysis for every HAE filing.
Synthesis (Verdict & Resolution)
The 10-K reveals a company at a critical inflection point, attempting to trade volume for value. While the shift toward higher-margin Hospital and Plasma technologies is evident in the gross profit growth, the overall revenue decline and significant impairments suggest the transition is fraught with execution risk. The company is effectively betting its future on the success of the Hospital segment and the integration of Vivasure to offset the decay in its legacy blood center business. Investors are left to weigh the impressive jump in operating cash flow against a precarious debt profile and the looming maturity of convertible notes. The success of the investment thesis depends on whether the operational leverage from the ERP rollout and the market penetration of new vascular closure products can outpace the structural decline of the core plasma and blood center franchises.
Core Takeaway
Haemonetics is successfully increasing its margin profile and cash flow, but is fighting a tide of declining overall revenue and significant debt obligations.
Investor Lens
The trade-off is between impressive operational efficiency (cash flow/margins) and deteriorating top-line growth and high leverage.
Watch Next
FDA approval status of the PerQseal Elite arterial closure system in the U.S.
Signal Momentum Chart
Quarterly net bull/bear signal ratio. Click nodes to select a quarter.
Signal Timeline
Filing History
The 10-K reveals a company at a critical inflection point, attempting to trade volume for value. While the shift toward higher-margin Hospital and Plasma technologies is evident in the gross profit growth, the overall revenue decline and significant impairments suggest the transition is fraught with execution risk. The company is effectively betting its future on the success of the Hospital segment and the integration of Vivasure to offset the decay in its legacy blood center business. Investors are left to weigh the impressive jump in operating cash flow against a precarious debt profile and the looming maturity of convertible notes. The success of the investment thesis depends on whether the operational leverage from the ERP rollout and the market penetration of new vascular closure products can outpace the structural decline of the core plasma and blood center franchises.
Disclaimer: The synthesis provided is generated by AI models and should not be construed as investment advice. Analysis is based solely on regulatory data present at the time of publication. Consult a financial advisor for specific investment strategies.